Boston Scientific Toasts 2003 On Heels Of 76% Stock Leap; Index Hungover

Boston Scientific appears poised to remain a Wall Street darling as the firm enters the new year with promising initial data on its Taxus drug-eluting stent, a reinvigorated cardiology business, an experienced management team and an industry-friendly FDA